In a breakthrough that bridges the gap between historical botanical mystery and modern pharmaceutical potential, a West Virginia University undergraduate student has identified a long-sought-after fungus that may hold the key to new treatments for depression, addiction, and post-traumatic stress disorder. Corinne Hazel, an environmental microbiology major and prestigious Goldwater Scholar hailing from Delaware, Ohio, discovered the previously elusive species while conducting research at the WVU Davis College of Agriculture and Natural Resources.

The organism, which Hazel has formally named Periglandula clandestina, was found thriving within the tissues of morning glory plants. Its discovery marks the conclusion of a decades-long scientific hunt for the biological source of specific chemical compounds that have fascinated researchers since the early 20th century. By identifying this symbiotic fungus, Hazel and her mentor, Daniel Panaccione, a Davis-Michael Professor of Plant and Soil Sciences, have opened a new frontier in the study of ergot alkaloids—the same class of compounds that Swiss chemist Albert Hofmann famously modified to create the semisynthetic drug LSD in the late 1930s.

The path to this discovery was one of meticulous observation and academic persistence. While working in Professor Panaccione’s laboratory, Hazel was engaged in a study focused on how morning glory plants disperse protective chemicals known as ergot alkaloids through their root systems. It was during this routine examination of plant samples that she caught sight of an anomaly.

"We had a ton of plants lying around and they had these tiny little seed coats," Hazel recalled. "We noticed a little bit of fuzz in the seed coat. That was our fungus."

That "little bit of fuzz" proved to be the missing piece of a botanical puzzle that had confounded researchers for generations. Recognizing the potential significance of the find, the team acted quickly to secure the evidence. Utilizing a student enhancement grant from the WVU Davis College, Hazel facilitated the preparation and genome sequencing of the fungus. The results were conclusive: the sample represented an entirely new, previously undescribed species. The genetic sequence has since been deposited in a national gene bank, officially bearing Hazel’s name as the discoverer.

For Professor Panaccione, the achievement is a testament to the capabilities of undergraduate researchers when given the right environment. "Sequencing a genome is a significant thing," he remarked. "It’s amazing for a student."

The scientific context of this discovery dates back to the early investigations of Albert Hofmann. After his accidental discovery of the psychedelic properties of LSD, Hofmann turned his attention to nature, suspecting that the morning glory plant—which contains high concentrations of lysergic acid derivatives—must harbor a hidden biological engine responsible for producing these substances.

"Morning glories contain high concentrations of similar lysergic acid derivatives that give them their psychedelic activities," Panaccione explained. "This inspired Hofmann and others to investigate morning glories for the presence of a hidden fungus related to the ergot fungus that might be the source of these chemicals. They found very similar chemicals, but they could never find the fungus itself."

For decades, the existence of a fungus living in symbiosis with the morning glory remained a compelling hypothesis, but physical evidence remained elusive. The name chosen by the researchers, Periglandula clandestina, serves as a permanent nod to this history; "clandestina" refers to the organism’s remarkable ability to remain hidden from investigators for so many years. The findings, recently published in the journal Mycologia, confirm that the fungus and the plant share a symbiotic relationship, with the fungus producing the very alkaloids that Hofmann sought to identify nearly a century ago.

Ergot alkaloids, while biologically potent, represent a complex subject in medicine and agriculture. They are produced exclusively by fungi, and while they are famously associated with morning glories, they are also frequently found on grains such as rye. When consumed in high concentrations or through contaminated crops, these alkaloids can be poisonous to both humans and livestock, causing severe health complications.

However, when refined and controlled, these same chemicals have proven to be powerful therapeutic tools. Currently, clinicians utilize various ergot-derived compounds to manage a spectrum of challenging conditions, including chronic migraines, dementia, uterine hemorrhaging, and Parkinson’s disease. The challenge for modern pharmacology lies in the "side effect profile" of these substances, which can often be severe.

This is where the discovery of Periglandula clandestina becomes particularly valuable. The fungus is noted for its high efficiency in producing ergot alkaloids in large quantities. By studying how this fungus functions and the specific compounds it creates, researchers hope to better understand the chemical pathways involved. This, in turn, could lead to more refined pharmaceutical applications that maintain the therapeutic benefits of the alkaloids while bypassing their dangerous side effects.

"Many things are toxic," Panaccione noted, reflecting on the dual nature of these compounds. "But if you administer them in the right dosage or modify them, they can be useful pharmaceuticals. By studying them, we may be able to figure out ways to bypass the side effects. These are big issues for medicine and agriculture."

The identification of the fungus is not merely a static discovery; it is a catalyst for ongoing research. Hazel is currently working to determine the most effective methods to culture the fungus, which has proven to be a slow-growing organism in the laboratory setting. Understanding the optimal conditions for its growth is a prerequisite for further biochemical analysis and potential drug development.

Beyond the immediate scope of Periglandula clandestina, the discovery raises broader questions about the biodiversity of plant-fungal symbioses. Hazel is now exploring whether other species of morning glory might also host their own unique, as-yet-undescribed fungal symbiotes that could produce similar or entirely different ergot alkaloid profiles.

"I think that’s the perfect name," Panaccione said of the new species. "And I love that we did this project together. Corinne has a ton of talent. It’s about students recognizing the opportunities, seizing them and having the skill and the brain power to bring this work to fruition."

For Hazel, the experience has been a transformative chapter in her academic career. Reflecting on the serendipitous nature of the discovery, she emphasized the importance of curiosity and readiness in the lab.

"I’m lucky to have stumbled into this opportunity," she said. "People have been looking for this fungus for years, and one day, I look in the right place, and there it is. I’m very proud of the work that I’ve done at WVU."

As the scientific community continues to explore the potential of psychedelics and their derivatives in treating mental health conditions like treatment-resistant depression and PTSD, the role of foundational research into natural sources becomes increasingly vital. By uncovering a secret that has been hidden in plain sight for decades, Hazel and her colleagues at West Virginia University have provided the field with a new, robust, and highly efficient subject for future study. The work serves as a reminder that the most significant breakthroughs often occur when rigorous academic discipline meets the humble, persistent observation of the natural world.